Crossject Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Crossject Aktie had revenue of €0 and net profit of -€8.58m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-11.89m	-
Net profit	-8.58m	-
EBITDA	-6.65m	-

Fundamentals

Metric	Value
Market capitalization	€84.88m
Number of shares	60.63m
52-week high/low	€2.70 - €1.10
Dividends	No
Beta	0.52
P/E ratio	-5.60
PEG ratio	0.47
P/B ratio	28.23
P/S ratio	0.00

Company profile

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.